Intraocular Lymphoma

  • George N. Magrath
  • Emil Anthony T. Say
Part of the Current Practices in Ophthalmology book series (CUPROP)


Intraocular lymphoma is one of the great masqueraders in ophthalmology. It is generally divided into vitreoretinal or uveal (iris, ciliary body, and choroid) lymphoma, and each may either be primary or secondary (metastatic). Despite similarities in patient demographic, nomenclature, and treatment, clinical manifestations and systemic prognosis are very different. Vitreoretinal lymphoma is considered a bilateral disease with central nervous system involvement, while uveal lymphoma is more often unilateral and isolated, resulting in a better systemic prognosis and patient survival.


Ocular oncology Retina Intraocular lymphoma Uveal lymphoma Choroidal lymphoma Iris lymphoma Ciliary body lymphoma 


  1. 1.
    Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36(6):564–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589–99.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Cooper EL, Riker JL. Malignant lymphoma of the uveal tract. Am J Ophthalmol. 1951;34(8):1153–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol. 2013;131(1):50–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Salomao DR, Pulido JS, Johnston PB, Canal-Fontcuberta I, Feldman AL. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma. JAMA Ophthalmol. 2013;131(9):1151–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Cao X, Shen D, Callanan DG, Mochizuki M, Chan CC. Diagnosis of systemic metastatic retinal lymphoma. Acta Ophthalmol. 2011;89(2):e149–54.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Taki R, Takeda A, Yoshikawa H, Fukuhara T, Arita R, Suehiro Y, et al. Clinical features of systemic metastatic retinal lymphoma in Japanese patients. Ocul Immunol Inflamm. 2017;25(5):654–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Gass JD, Sever RJ, Grizzard WS, Clarkson JG, Blumenkranz M, Wind CA, et al. Multifocal pigment epithelial detachments by reticulum cell sarcoma. A characteristic funduscopic picture. Retina. 1984;4(3):135–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Pang CE, Shields CL, Jumper JM, Yannuzzi LA. Paraneoplastic cloudy vitelliform submaculopathy in primary vitreoretinal lymphoma. Am J Ophthalmol. 2014;158(6):1253–61.e2.PubMedCrossRefGoogle Scholar
  10. 10.
    Casady M, Faia L, Nazemzadeh M, Nussenblatt R, Chan CC, Sen HN. Fundus autofluorescence patterns in primary intraocular lymphoma. Retina. 2014;34(2):366–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Fardeau C, Lee CP, Merle-Beral H, Cassoux N, Bodaghi B, Davi F, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma. Am J Ophthalmol. 2009;147(5):886–94. 94.e1.PubMedCrossRefGoogle Scholar
  12. 12.
    Barry RJ, Tasiopoulou A, Murray PI, Patel PJ, Sagoo MS, Denniston AK, et al. Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: a novel aid to early diagnosis. Br J Ophthalmol. 2018;102(10):1362–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Mruthyunjaya P, Jumper JM, McCallum R, Patel DJ, Cox TA, Jaffe GJ. Diagnostic yield of vitrectomy in eyes with suspected posterior segment infection or malignancy. Ophthalmology. 2002;109(6):1123–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Chan CC. Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc. 2003;101:275–92.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Pulido JS, Salomao DR, Frederick LA, Viswanatha DS. MyD-88 L265P mutations are present in some cases of vitreoretinal lymphoma. Retina. 2015;35(4):624–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol. 2015;133(2):191–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med. 2013;15(81):93–100.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Pe’er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2009;17(5):299–306.PubMedCrossRefGoogle Scholar
  19. 19.
    Shields CL, Sioufi K, Mashayekhi A, Shields JA. Intravitreal melphalan for treatment of primary vitreoretinal lymphoma: a new indication for an old drug. JAMA Ophthalmol. 2017;135(7):815–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Berenbom A, Davila RM, Lin HS, Harbour JW. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond). 2007;21(9):1198–201.CrossRefGoogle Scholar
  21. 21.
    Hoffman PM, McKelvie P, Hall AJ, Stawell RJ, Santamaria JD. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (Lond). 2003;17(4):513–21.CrossRefGoogle Scholar
  22. 22.
    Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115(9):1152–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109(9):1709–16.PubMedCrossRefGoogle Scholar
  24. 24.
    Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92(3):383–8.PubMedCrossRefGoogle Scholar
  25. 25.
    de Smet MD. Management of non Hodgkin’s intraocular lymphoma with intravitreal methotrexate. Bull Soc Belge Ophtalmol. 2001;279:91–5.Google Scholar
  26. 26.
    Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, et al. Intraocular use of rituximab. Eye (Lond). 2007;21(12):1524–7.CrossRefGoogle Scholar
  27. 27.
    Mashayekhi A, Shukla SY, Shields JA, Shields CL. Choroidal lymphoma: clinical features and association with systemic lymphoma. Ophthalmology. 2014;121(1):342–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Aronow ME, Portell CA, Sweetenham JW, Singh AD. Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology. 2014;121(1):334–41.PubMedCrossRefGoogle Scholar
  29. 29.
    Tavallali A, Shields CL, Bianciotto C, Shields JA. Choroidal lymphoma masquerading as anterior ischemic optic neuropathy. Eur J Ophthalmol. 2010;20(5):959–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Pelegrin L, Adan A, Lopez-Guillermo A, Martinez A, Shields CL. An old disease in an atypical place. Surv Ophthalmol. 2014;59(6):660–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Velez G, de Smet MD, Whitcup SM, Robinson M, Nussenblatt RB, Chan CC. Iris involvement in primary intraocular lymphoma: report of two cases and review of the literature. Surv Ophthalmol. 2000;44(6):518–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Mashayekhi A, Shields CL, Shields JA. Iris involvement by lymphoma: a review of 13 cases. Clin Exp Ophthalmol. 2013;41(1):19–26.PubMedCrossRefGoogle Scholar
  33. 33.
    Chang TS, Byrne SF, Gass JD, Hughes JR, Johnson RN, Murray TG. Echographic findings in benign reactive lymphoid hyperplasia of the choroid. Arch Ophthalmol. 1996;114(6):669–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Schubert CGAS, Shields CL. The seasick pattern of choroidal lymphoma on enhanced depth imaging optical coherence tomography. Retina. 2014;34(8):1495–512.CrossRefGoogle Scholar
  35. 35.
    Shields CL, Arepalli S, Pellegrini M, Mashayekhi A, Shields JA. Choroidal lymphoma shows calm, rippled, or undulating topography on enhanced depth imaging optical coherence tomography in 14 eyes. Retina. 2014;34(7):1347–53.PubMedCrossRefGoogle Scholar
  36. 36.
    Grossniklaus HE, Martin DF, Avery R, Shields JA, Shields CL, Kuo IC, et al. Uveal lymphoid infiltration: report of four cases and clinicopathologic review. Ophthalmology. 1998;105(7):1265–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Cockerham GC, Hidayat AA, Bijwaard KE, Sheng ZM. Re-evaluation of “reactive lymphoid hyperplasia of the uvea”: an immunohistochemical and molecular analysis of 10 cases. Ophthalmology. 2000;107(1):151–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Mashayekhi A, Hasanreisoglu M, Shields CL, Shields JA. External beam radiation for choroidal lymphoma: efficacy and complications. Retina. 2016;36(10):2006–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • George N. Magrath
    • 1
  • Emil Anthony T. Say
    • 1
  1. 1.Storm Eye InstituteMedical University of South CarolinaCharlestonUSA

Personalised recommendations